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Abstract 
Aims: To assess the clinical value of measuring right atrial pressure (RAP) using 
near-infrared spectroscopy (NIRS) in patients with chronic heart failure (CHF). 
Methods and results: RAP was measured non-invasively using NIRS over the 
external jugular vein (Venus 1000, Mespere LifeSciences, Canada) in ambulatory 
patients with CHF enrolled in the Studies Investigating Co-morbidities Aggravating 
Heart Failure (SICA-HF) programme. Comparing 243 patients with CHF (mean age 
71 years; mean left ventricular ejection fraction (LVEF) 45%, median NT-proBNP 
788 ng/L) to 49 controls (NT-proBNP 125 ng/L), RAP was 7 [interquartile range 
(IQR) 4 – 11] mmHg vs. 4 (IQR 3 – 8) mmHg (P < 0.001). Those with RAP>= 10 
mmHg (n = 75) were older, had more severe clinical congestion and renal 
dysfunction, higher plasma NT-proBNP, larger left atrial volume, higher systolic 
pulmonary pressure and were more often in atrial fibrillation but their LVEF was 
similar to patients with lower RAP. During a median follow-up of 595 (IQR: 492 – 
714) days, 49 patients (20%) died or were hospitalized for worsening CHF. 
Compared with patients with RAP<= 5 mmHg, those with RAP>= 10 mmHg had a 
greater risk of an event (hazard ratio 2.38, 95% confidence interval 1.19 – 4.75, P = 
0.014). RAP measured by NIRS predicted outcome, competing with NT-proBNP in 
multivariable models.  
Conclusions: Measuring RAP using NIRS identifies ambulatory patients with CHF 
who have more severe congestion and a worse outcome. The device might be a 
useful objective method of monitoring RAP, especially for those inexperienced in 
eliciting physical signs or when measurement of natriuretic peptides is not 
immediately available. 
  
Introduction 
An increased jugular venous pressure (JVP), reflecting raised right atrial pressure (RAP), is 
not only a classical sign of congestive heart failure (CHF) but also a powerful predictor of an 
adverse outcome.1 
 
When the JVP is raised, expert doctors are likely to make a correct diagnosis of congestion 
and impaired haemodynamics;2 however, assessing the JVP is challenging, and many 
clinicians are neither familiar with its measurement nor skilled in its interpretation.3,4 
Measurement of inferior vena cava (IVC) or internal jugular vein diameter (JVD) by 
ultrasound provide an indirect estimate of RAP, and identify with more precision patients 
with heart failure (HF) who are congested and at high risk of adverse events;5 – 8 however, 
these ultrasonic methods require specific probes and trained personnel. 
Although the discovery of near-infrared energy dates to the beginning of the 19th century,9 it 
is only recently that interest in near-infrared spectroscopy (NIRS) has grown as a tool for 
medical research that might have a wide range of clinical applications.10 – 12  
NIRS of the external jugular vein allows easy, quick, and non-invasive estimation of RAP. 
We investigated whether NIRS-derived RAP readings are clinically relevant by relating them 
to other clinical, biochemical, and ultrasound indices of cardiac dysfunction and congestion, 
and by assessing their prognostic value in outpatients with HF. 
 
Methods 
Study population 
Between April 2013 and April 2014, consecutive control subjects and patients with HF were 
enrolled in Kingston-Upon-Hull, UK, for the Studies Investigating Co-morbidities 
Aggravating Heart Failure (SICA-HF, ClinicalTrials.gov Identifier: NCT01872299).13 SICA-
HF is an international observational study of the prevalence, incidence, and impact of key co-
morbidities in outpatients with a clinical diagnosis of HF. For the purpose of this analysis, we 
considered patients to have cardiac dysfunction as the likely cause of HF symptoms if they 
had  left ventricular ejection fraction (LVEF) 50% or a raised NT-proBNP (>125 ng/L).14 
Patients with end-stage renal failure or on renal dialysis, an alternative cause for raised NT-
proBNP, were not enrolled in this study. 
Controls were subjects aged >60 years who had no history of   HF who were recruited to the 
SICA-HF study by invitation from primary care practice lists, the majority of whom had 
hypertension or type 2 diabetes. All control subjects had to have normal left ventricular 
function on echocardiography and a plasma NT-proBNP <125 ng/L. 
Patients were managed according to contemporary guidelines and assessed after optimization 
of their medical therapy. Patients provided a detailed clinical history and blood tests 
(including haematology, biochemistry profile, and NT-proBNP) and had an 
electrocardiogram and echocardiogram on the same day. Patients in atrial fibrillation or atrial 
flutter were grouped as ‘AF’. 
Patients were followed up until 30th June 2015. The primary out- come of interest was a 
composite of HF hospitalization or all-cause mortality. Our hospital is the only one in the 
region offering acute medical services. With the consent of patients, we have access to both 
primary and secondary care records. Outcome is censored at the point of last medical contact 
in primary or secondary care. Data regarding deaths and hospitalizations were collected from 
the hospital’s electronic systems, supplemented by information from patients, discharge 
letters, and their family doctors. Hospitalizations were considered to be HF-related if the 
discharge letter suggested HF as a key reason for admission. All data regarding admissions 
and deaths were entered into a dedicated on-line database, and were adjudicated at regular 
intervals by different researchers blind to any other measurements made at the time of the 
clinical visit. 
The investigation conformed to the principles outlined in the Declaration of Helsinki and was 
approved by relevant ethical bodies. All subjects gave their written informed consent. 
 
Clinical examination 
Clinical examinations were performed by an experienced doctor (P.P.) before 
echocardiography and NIRS evaluation. A clinical congestion score was applied, based on 
lung auscultation (normal, presence of basal, mid-zone, or diffuse crackles), JVP (not visible, 
raised 1 –4 cm, raised to earlobe), peripheral oedema (none, ankles, below or above knees) 
and liver examination (not palpable, palpable) with one point attributed for each degree of 
severity. Patients with a score of three or more out of a possible score of nine were defined as 
being congested.15 
 
Near-infrared spectroscopy measurements 
Following clinical examination and before echocardiography, with the patient reclining, and 
head and neck elevated at 45∘, RAP was measured using NIRS (Venus 1000, Mespere 
LifeSciences, Canada, Figure 1), a portable device that includes adhesive patches connected 
to a reading electrode placed over the external jugular vein on the right side of the neck and a 
reference point aligned with the right atrium (the fourth intercostal space at the mid-
anteroposterior diameter of the chest wall). NIRS works by projecting near-infrared light into 
the neck tissue adjacent to the external jugular vein to detect and analyse reflected light. As 
the absorption of near-infrared light is mainly by haemoglobin, variations in the amplitude of 
reflected light are related to pulsations in the superficial external jugular vein. Once the 
jugular venous pulse is detected, pressure is measured compared with a zero-reference, 
usually the 4th intercostal space in the mid-anteroposterior diameter of the chest wall. If the 
height of the JVP is above or below the reading electrode, the device prompts adjustment of 
the slope at which the patient is lying. Once stable waveforms and readings are obtained, the 
device records RAP (in mmHg). It takes about 2 min to conduct the test. 
 
Echocardiographic measurements 
Echocardiography was performed by a single operator (A.K.-B.) using a Vivid Seven (GE 
Healthcare, UK) system operating at 1.7–3.4 MHz. Doppler tracings and two-dimensional 
images were obtained from parasternal long- and short-axis, apical, and subcostal views. 
Echocardiograms were stored and reviewed by the same operator blinded to other patient 
details using an EchoPAC station (GE Healthcare, UK). LVEF was measured using 
Simpson’s biplane method. Left atrial volume was measured in the four-chamber view and 
indexed to body surface area. Tricuspid annular plane systolic excursion (TAPSE) was used 
to assess right ventricular systolic function. The maximum trans-tricuspid systolic gradient 
was also measured by echocardiography (based on the modified Bernoulli equation, ΔP = 
Max tricuspid regurgitation velocity2 × 4). With the patient in the supine position, the 
maximum IVC diameter during the respiratory cycle was measured between 1 and 3 cm 
before merger with the right atrium. 
 Jugular vein ultrasound assessment 
We have previously reported the method and reproducibility for measuring JVD ratio.5,6 With 
the patient  reclining  and  head  and neck elevated at 45∘, a linear high-frequency probe (10 
MHz) was placed on the left side of the neck below the angle of the jaw and moved inferiorly 
toward the angle of Louis until the left internal jugular vein was identified. Internal JVD and 
its changes were then measured continuously by M-mode or in the 2-dimensional frame at 
rest (expiratory phase), during a Valsalva manoeuvre (performed by forceful expiration 
against a closed glottis) and, finally, during deep inspiration by A.K.-B. The ratio between 
maximum JVD during Valsalva and JVD at rest was calculated (JVD ratio). 
 
Statistical methods 
Categorical data are presented as percentages, normally distributed continuous data 
as mean ± standard deviation (SD), and non-normally distributed variables as 
median and interquartile range (IQR). 
Patients with HF were grouped by normal (<= 5 mmHg), borderline (6 – 9 mmHg), 
or raised (>=10 mmHg) RAP. One-way ANOVA and Kruskal – Wallis tests were 
used to compare continuous variables between groups depending on the normality 
of the distribution, and the 𝜒𝜒2 test was used for categorical variables. 
Different multivariable models were tested using a limited number of variables to 
prevent statistical overfitting. In Model A, we chose, prospectively, five candidate 
variables of interest [age, NYHA class, creatinine, LVEF, and log(NT-proBNP)] in 
addition to RAP; for Model B (biochemical), we selected the biochemical variables 
that were most strongly associated with prognosis in univariable analysis, in 
addition to age, log(NT-proBNP) and RAP; for model C (echocardiography) we 
selected echocardiographic variables strongly associated with outcome in 
univariable analysis, including and excluding IVC diameter, in addition to age and 
RAP. 
Treatment variables were not included in models as these might be confounded by 
indication and might vary over time. We did not include mitral and tricuspid 
regurgitation because their estimation was semi-quantitative and because we 
included patients with AF, which might make the interpretation of valvular 
regurgitation difficult. Forward and backward procedures were used to determine 
which variables independently predicted the primary composite outcome. 
Assumptions of the models were tested, such as multicollinearity and proportional 
hazards. 
Kaplan – Meier curves with the log-rank statistic were used to illustrate outcome. 
All the analyses were performed using SPSS v.22 and Stata software. A two-sided P-value 
<0.05 was considered statistically significant. 
 
Results 
Patient characteristics 
The mean age of patients with CHF (n = 243, Table 1) was 71 (±10) years, 36% were women, 
58% had ischaemic heart disease (IHD) and 28% had AF. Mean LVEF was 45 (±13)% and 
median plasma NT-proBNP was 788 (280 – 1481) ng/L. Approximately 80% of patients were 
treated with beta-blockers and ACE inhibitors and 63% were taking loop diuretics. 
Amongst controls (n = 49), 84% had diabetes, 69% had hyper- tension, and 16% IHD. Their 
mean age was 72 (±8) years, 49% were men; mean LVEF was 60 (±5)% and median NT-
proBNP 72 (45 – 104) ng/L. 
 
Reproducibility of measurements of right atrial pressure by near-infrared spectroscopy 
RAP by NIRS was measured separately by two operators blind   to each other’s results in 20 
patients.  The reproducibility  of  RAP measurements was tested using the Bland – Altman 
method. Inter-operator reproducibility of RAP was good [Supplementary material online, 
Figure S1; mean difference for RAP (±SD): 0.3 (±1.8) mmHg; upper and lower limit of 
agreement: 3.8 mmHg−3.2 mmHg, with no value outside limits of agreement]. Moving the 
reference point from the 4th to 3rd intercostal space led to slightly lower readings [mean 3.4 
(±4.1) mmHg vs. 4.8 (±3.6) mmHg, P = 0.001], but moving the reference point from the 4th 
to 5th did not significantly affect results [4.7 (±4.4) mmHg vs. 4.8 (±3.6) mmHg, P = 0.68; 
Supplementary material online, Figures S2 and S3, for Bland– Altman plots]. The 
distribution of RAP measured by NIRS in patients with HF and controls is shown in 
Supplementary Figure S4. 
 
Right atrial pressure by near-infrared spectroscopy, clinical and echocardiographic 
findings 
RAP by NIRS could be obtained in all patients; RAP was higher in patients with HF than 
controls. Amongst patients with CHF, those with RAP >= 10 mmHg were older, were more 
symptomatic, had worse renal function and lower haemoglobin, were more likely to have AF 
and a clinically raised JVP, and had more clinical and biochemical (NT-proBNP) signs of 
congestion (Table 1). They had larger left ventricular and atrial volumes, worse right 
ventricular systolic function, higher systolic pulmonary pressure, greater IVC and JVD 
(Table 1) and a lower JVD ratio on echocardiography. Patients with more severe mitral or 
tricuspid regurgitation also had higher RAP (Supplementary material online, Table S1). 
However, there was no relation between RAP and sex, IHD, diabetes, hypertension, or 
chronic obstructive pulmonary disease. 
Of  patients  with  RAP<=5 mmHg,  50%  had  a  normal  IVC ( <= 16 mm), 10% had a JVD 
ratio <=  4 (abnormal), and 17% had a dilated IVC (>20 mm) compared with 12%, 40%, and 
50%, respectively, of those with RAP >= 10 mmHg (Table 1). 
There was a positive correlation between RAP and age, left atrial volume index, systolic 
pulmonary pressure, IVC diameter, NT-proBNP, and JVD at rest and during deep inspiration 
(and decreasing JVD ratio). There was a negative correlation between RAP and haemoglobin 
and creatinine (Table 2). 
Of patients with RAP <= 5 mmHg, 79 (98%) had a clinically normal JVP and, conversely, of 
50 patients who were thought to have a clinically elevated JVP, only one had a RAP by NIRS 
of <5 mmHg. However, 44 patients thought to have a clinically normal JVP had RAP >= 10 
mmHg. Amongst patients with a clinically normal JVP, those who had a RAP >= 10 mmHg 
had a higher plasma NT-proBNP and lower haemoglobin, a larger left atrial and IVC 
diameter, and higher tricuspid regurgitation gradient (Supplementary material online, Table 
S2). 
 
Outcome 
During a median follow-up of 595 (IQR 491 –714) days, there were 49 primary outcomes 
amongst patients with HF of which 25 first events were HF hospitalizations and 24 were 
deaths. Overall, there were 27 deaths amongst patients with HF of which 70% were 
cardiovascular deaths. There was one HF hospitalization amongst the control group and no 
deaths. 
In univariable Cox regression analysis (Table 3), higher JVP assessed clinically, by IVC 
ultrasound, or RAP by NIRS, were associated with an increased risk of adverse outcome. In 
multivariable models, increasing log(NT-proBNP) (Model A and B), albumin (Model B), and 
IVC diameter (Model C) were independently related to an adverse outcome, competing with 
RAP in the models (Table 4). 
Compared with patients with RAP< 5 mmHg, those with RAP >=10 mmHg measured by 
NIRS had a higher risk of an adverse outcome [hazard ratio (HR) 2.38, 95% confidence 
interval (CI) 1.19–4.75, P = 0.014, Figure 2]. 
Compared with patients who had a low JVP both clinically and with NIRS (n = 79), those 
with low JVP clinically but high RAP with NIRS (n = 44) had nearly a two-fold increased 
risk of death or admission with HF, although this did not reach statistical difference (HR 1.93, 
95% CI 0.85 – 4.37; P = 0.12), probably reflecting the low number of patients and events 
(Supplementary material online, Figure S5). 
 
Discussion 
Measuring RAP with NIRS identifies outpatients with HF who have more evidence of 
clinical, biochemical, or echocardiographic congestion, and who are at greater risk of an 
adverse outcome. RAP measured by NIRS also identified patients with more severe 
congestion amongst those whose JVP was considered to be clinically normal. 
A clinically raised JVP has high specificity in the assessment of volume overload but is 
insensitive. Moreover, inter-observer variability is substantial and dependent on experience 
and skills,16 the time and care taken to examine the patient, anatomical differences 
(particularly in the circumference of the neck) and swings in intra-thoracic pressure due to 
pulmonary disease. 
Although the art of physical examination remains the cornerstone of the evaluation of 
patients with HF,17 it often fails to detect subclinical congestion. In addition, clinical skills 
may be declining due to changes in training and the widespread availability and use of 
diagnostic imaging or biological tests.18 In an era dominated   by the dilemma of treating 
increasing numbers of patients with chronic illnesses without a corresponding increase in 
resources, there is a growing trend to rely on nurses and less experienced doctors to assess 
and manage patients. Adding measurement of RAP using NIRS to measurements of weight, 
heart rate and rhythm, and blood pressure done routinely by clinical assistants can easily be 
implemented even in a busy clinic. This could help identify patients with residual congestion 
and a worse prognosis who might benefit from adjustment in therapy. Using measurements of 
RAP to tailor diuretic dose for individual patients might merely be considered good clinical 
practice but, as with any new technology, it is important not to jump to conclusions but rather 
prove that preconceptions are correct. 
Assessing IVC or internal JVD ultrasonically provides similar diagnostic and prognostic 
information to measurement of natriuretic peptides, and are valid alternatives to assess 
patients’ fluid status. Measurements of IVC diameter or internal JVD are objective, 
recordable, and reproducible measures of congestion5 – 8 that predict outcome. However, such 
measurements require additional time, expertise, and special probes. Moreover, although 
echocardiography might  be  done  routinely  when  the  patient is first referred, it will often 
not be repeated routinely at follow-up clinics. This might allow progression of  the  
underlying disease to be missed. NIRS can also be measured in patients who are unable to 
cooperate with simple instructions, such  as  Valsalva  or  other  respiratory  manoeuvres,  or  
in frail patients who may not tolerate long and detailed echocardiographic studies. 
 
Limitations 
The sample size is relatively small, and the number of events relatively few.  Further, larger,  
multi-centre studies are  required to confirm our findings. Although we found good 
correlations between RAP measured by NIRS and echocardiographic indices of congestion, 
we did not collect invasive haemodynamic data in our patients. However, others have shown 
that RAP measured by NIRS is accurate compared with invasive measurements.19 
Although reproducibility was good, we found greater variability for lower RAP 
measurements, perhaps reflecting difficulties in identifying the jugular vein when RAP is not 
substantially raised. A potential source of error is the zero-reference placement which might 
lead to under- or overestimation of readings. 
We included a broad range of patients with cardiac dysfunction. Some patients will not have  
fulfilled enough criteria to be considered to have HF by some experts. However, this analysis 
was not designed as a diagnostic exercise but rather to investigate the range  and  significance  
of  RAP  measured  by NIRS in a relevant population.  A population  of  patients  with 
narrowly defined HF might be considered to be of less interest. 
Our control group consisted of many patients with or at high risk of cardiovascular disease 
already receiving ACE inhibitors, beta-blockers, and diuretics; it is possible that treatment 
had normalized circulating levels of NT-proBNP and RAP. Thus, there is likely to be some 
overlap between patients in the disease and control groups in the present study. We believe 
that this is a strength, rather than a weakness, since it should be much easier to detect a 
difference if the control group had been fit, young, healthy individuals. One patient in the 
control group did subsequently have a HF-related hospitalization but many more occurred in 
patients with HF even when RAP was <=5 mmHg (similar to controls) (HR 7.59, 95% CI 
0.99 – 58.41, P = 0.05). 
 
Conclusions 
Evaluation of RAP using NIRS identifies outpatients with HF who have a higher risk of an 
adverse outcome. This device might be used for the rapid bedside evaluation of RAP and 
congestion in patients with HF, especially when it cannot be assessed confidently by clini- 
cians and measurement of natriuretic peptides are not immediately available. 
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Figure legend 
Figure 1: Measurement of right atrial pressure using near-infrared spectroscopy. With 
the patient reclining  and  head and neck elevated at 45∘, the external jugular vein was 
identified and right atrial pressure measured using near-infrared spectroscopy (Venus 
1000, Mespere LifeSciences, Canada), a portable device that includes adhesive patches 
connected to a reading electrode placed over the external jugular vein on the right side 
of the neck and a reference point aligned with the right atrium (the fourth intercostal 
space at the mid-anteroposterior diameter of the chest wall). Once stable waveforms 
and readings are obtained, the device records right atrial pressure (in mmHg). 
Figure 2:  Kaplan – Meier curves for the primary outcome of death from all causes and 
heart failure (HF) hospitalizations. Compared with those with normal right atrial 
pressure (RAP) by near-infrared spectroscopy (≤5 mmHg, in red), HF patients with 
high RAP (≥10 mmHg,  in yellow) had more than a two-fold higher risk of dying or 
being hospitalized for HF (hazard ratio 2.38, 95% confidence interval  1.19 – 4.75, P = 
0.014). 
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